• Similar articles
    Trending: Manas Mishra
    Manas Mishra
    Johnson & Johnson to buy Momenta for about US$6.5 billion
    Aug 19 2020. Inc for about US$6.5 billion in cash to expand into the area of autoimmune disease treatments. J&J will pay US$52.50 for each Momenta share, a 70.4per cent premium to Tuesday's closing price. Reporting by Manas Mishra in Bengaluru;…
    Inc for about US$6.5 billion in cash to expand into the area of autoimmune disease treatments. J&J will pay US$52.50 for each Momenta share, a 70.4per cent premium to Tuesday's closing price. Reporting by Manas Mishra in Bengaluru;…
    Channelnewsasia
    Similar
    Pfizer signs deal to manufacture Gilead's remdesivir for COVID-19
    Aug 7 2020. Britain's Hikma Pharmaceuticals has started manufacturing remdesivir at its Portugal plant, the British company's chief executive officer said on Friday. (Reporting by Manas Mishra in Bengaluru; Editing by Anil D'Silva)…
    Britain's Hikma Pharmaceuticals has started manufacturing remdesivir at its Portugal plant, the British company's chief executive officer said on Friday. (Reporting by Manas Mishra in Bengaluru; Editing by Anil D'Silva)…
    Channelnewsasia
    Similar
    4per cent rise in second-quarter profit on Thursday, helped by demand for its diabetes (illustration) drug, Trulicity.… dream designsChannelnewsasia
    Eli Lilly's profit rises 6.4per cent on diabetes drug strength
    Jul 30 2020. Health: …based companies that had successful initial public offerings in the second quarter of 2020. Reporting by Manas…
    …based companies that had successful initial public offerings in the second quarter of 2020. Reporting by Manas…
    Channelnewsasia
    Similar

    About NewsOwner

    We are tracking and analysing news

    Add website

    Send us news sources you want us to cover

    Advertise

    Advertising and sponsored content

    Contact us

    Send us your comments or questions here

    Copyrights © 2016 - Scanmine Inc. / NewsOwner.com. This publication is automatically generated based on content updated from thousands of sources. All article content are © copyright of their respective owners. Third party content is collected from open sources only and selected, filtered and used by the creator of this publication similar to how third party content is posted by users in social media platforms or generated from search engines and in line with the U.S. "Fair Use Act" and similar laws in other countries allowing limited use of copyrighted material.